Newsroom > Ethypharm consolidates its European presence with the integration of Altan, now led by Manuel Casegas as its General Manager
Thursday 14 October 2021 - 14h00
Ethypharm consolidates its European presence with the integration of Altan, now led by Manuel Casegas as its General Manager
Saint-Cloud, France – October 14th, 2021 – Ethypharm is pleased to announce that it has successfully completed the acquisition of Altan and has now welcomed into the group all of its employees. Led by Manuel Casegas, this new affiliate gives Ethypharm a direct presence in Spain and expands its hospital injectables portfolio and R&D pipeline. Ethypharm continues its ambitious growth strategy and consolidates its direct presence in Europe. With the integration of Altan, Ethypharm establishes itself in the fifth-largest pharmaceutical market in Europe and the eighth-largest market worldwide in terms of revenue. Ethypharm also benefits from an enlarged portfolio of high-quality hospital injectable products and a rich pipeline of R&D projects, which perfectly fit in the focus of the company.
To lead its new affiliate in Spain, Ethypharm has appointed Manuel Casegas as General Manager. “Given his role as Chief Industrial Officer of Altan over the past 3 years, Manuel Casegas knows very well Altan, its products and its teams. Ethypharm and Altan are highly complementary. In making this choice, we wanted to ensure business continuity. We trust that under Manuel’s leadership, Altan’s business will continue to grow and thrive, with an ambition higher than ever before.” comments Jean Monin, Chief Commercial Operations Officer of Ethypharm.
Manuel Casegas graduated as a pharmacist from the University of Burgundy in France. After close to 20 years at Roche and Famar, he took over the responsibility of the industrial operations of Altan three years ago. “Integrating Ethypharm is a major milestone for Altan” said Manuel Casegas. “As Ethypharm’s General Manager in Spain, my first priority will be to ensure a rapid and smooth integration of Altan into Ethypharm so as to make the most of our combined strengths to serve health and patients.”
With this acquisition Ethypharm now has a full presence in the top 5 European markets and net sales of close to 400M€ (2020).
Ethypharm is a European pharmaceutical company focused on two areas: the Central Nervous System and Hospital injectables. Ethypharm markets its drugs directly in Europe and China, and with partners in North America and the Middle East where its drugs are in high demand. The Group employs 1,750 people, mainly in Europe and China. Ethypharm works closely with authorities and healthcare professionals to ensure the appropriate use of and access to its medicines, by as many people as possible.